Results 21 to 30 of about 3,965 (158)

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian, Hussein Abu Daya, Arka Chatterjee, Firas Al Solaiman, Mark F. Sasse, William S. Fonbah, Raymond W. Workman, Brittany E. Johnson, Sarah E. Carlson, Brigitta C. Brott, Sumanth D. Prabhu, Massoud A. Leesar   +11 more
doaj   +1 more source

Early versus delayed, provisional eptifibatide in acute coronary syndromes [PDF]

, 2009
BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown.
Giugliano, RP, Armstrong, PW, White, JA, Bode, C, Lee, KL, van, 't Hof A, Strony, JT, Berdan, LG, Montalescot, G, Lewis, BS   +9 more
core   +2 more sources

Complications and management of eptifibatide-induced thrombocytopenia

, 2021
Background: Eptifibatide is used in acute coronary syndromes to reversibly block platelet aggregation by inhibiting the platelet glycoprotein IIb/IIIa receptor.
Ehrenpreis, Eli, Masood, Faisal, Chaus, Adib, Hertsberg, Anna, Hashmi, Saad   +4 more
core   +1 more source

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion

BMC Cardiovascular Disorders, 2002
Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj   +1 more source

Eptifibatide-induced acute profound thrombocytopenia in a patient with left main artery plaque rupture complicated by cardiogenic shock and gastrointestinal bleeding

Journal of Clinical and Preventive Cardiology, 2021
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal, William Van Gaal, Francis A Ponnuthurai   +2 more
doaj   +1 more source

A rare case of eptifibatide-induced thrombocytopenia

Journal of Community Hospital Internal Medicine Perspectives, 2021
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar, Kira MacDougall, Mira Alsheikh, Sara Parylo, Yevgeniy Skaradinskiy   +4 more
doaj   +1 more source

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

How safe is eptifibatide during urgent carotid artery stenting?

Frontiers in Neurology, 2013
Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam, Nirav eVora, Randall eEdgell, Richard Charles Callison, Yasir eAl Khalili, Michelle eStorkan, Amer eAlshekhlee, Amer eAlshekhlee   +7 more
doaj   +1 more source

Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice

The Turkish Journal of Gastroenterology, 2020
Background/Aims: To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease. Methods and Material: This study was designed as a controlled, animal, drug safety
Stanko S. Petrovic, Milijana M. Vasiljevska, Slobodan D. Obradovic, Dino K. Tarabar, Radoje B. Doder, Ivana J. Majstorovic, Marijana D. Petrovic, Zvonko M. Magic, Bojana M. Cikota, Nenad J. Perisic, Irina A. Brcerevic, Nebojsa S. Manojlovic, Nemanja K. Rancic   +12 more
doaj   +1 more source

Design of termo-sensitive molecularly imprinted polymers(MIP) and in vitro evaluation of controlled release of Eptifibatide drug [PDF]

شیمی کاربردی روز
In this research, a nano polymer was fabricated via the molecular imprinted polymer (MINP) method to transport and control the release of the drug eptifibatide.
Sharif Kaamyabi, Negar Karimi Hajishoreh, Abolfazl Akbarzadeh   +2 more
doaj   +1 more source